BIIB022 is a human IgG4 monoclonal antibody (mAb) targeting IGF1R/CD221. It inhibits the phosphorylation of IGF-1 and IGF-2-induced IGF-1R and its downstream substrates. BIIB022 is applicable for research in lung cancer, pancreatic cancer, and colon cancer. The recommended isotype control is Human IgG4 kappa, Isotype Control.
Target-Kategorie:
IGF-1R
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten